Secondary endpoint results of the first multicentric randomised phase II trial investigating the antitumour efficacy of 177Lutetium-DOTA-Octreotate (OCLU) in advanced progressive neuroendocrine pancreatic tumour: The OCLURANDOM trial

#4562

Introduction: No published randomised trial investing the role of PRRT (177Lutetium-DOTA-Octreotate) in advanced progressive PaNET patients.

Aim(s): We report for the first time the secondary endpoint results of the completed OCLURANDOM trial (EudraCT N°:2013-004032-30): best tumour response and duration according to local RECIST1.1, PFS, overall survival, safety (NCI CTCAE v.4), quality of life (EORTC QLQ GI NET 21/QLQC30), long-term safety.

Materials and methods: Patients with progressive advanced pancreatic NET within 1 year were randomised 1:1 to 177Lutetium-DOTA-Octreotate (OCLU, 7.4 GBqX4/8w) or sunitinib (SUN) 37.5 mg/d. 67% or 63% of patients of the OCLU arm vs. SUN arm, received SUN or PRRT, as one of subsequent lines.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Walter T, Beron A, Smith D, Deandreis D,

Keywords: Pancreatic neuroendocrine, randomised phase 2 trial, Lutathera, Sunitinib,